News
-
-
-
PRESS RELEASE
EQS-Adhoc: AMAG Austria Metall AG: AMAG Austria Metall AG: Impairment requirement affects EBIT in FY 2024; EBITDA range remains unchanged
AMAG Austria Metall AG expects EBIT reduction in FY 2024 due to impairment charges while EBITDA range remains unchanged. Details on impairment impact and future profitability -
PRESS RELEASE
Verisante Technology, Inc. Announces RTO Update:
SunRegen Healthcare AG closes $2.1 million private placement, advancing towards RTO with Verisante. SunRegen focuses on developing neurodegenerative drugs, starting with compound SBC003. Verisante to acquire 100% interest in SunRegen, aiming to qualify as Tier 2 Life Sciences Issuer -
-
-
-
PRESS RELEASE
Forum Ventures Releases Report Analyzing Venture Capital Activity in 2024 and Shifting Market Trends Heading into 2025
Forum Ventures releases report on navigating evolving VC strategies for fundraising in 2025 amidst market slowdown. Focus on AI, founder, traction metrics, bridge rounds & geographic shifts highlighted -
PRESS RELEASE
Cimulate Raises $28 Million in Series A Funding Led by Spark Capital to Transform Commerce with AI-Powered CustomerGPT
Cimulate raises $28M led by Spark Capital to revolutionize commerce search with CustomerGPT, delivering transformative customer experiences through scalable personalization -
PRESS RELEASE
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA
Regulatory approval for Phase I clinical trial of CD123-specific autologous CAR T-cell therapy by UHKT showcases Linea DNA as a rapid and cost-efficient manufacturing solution for AML treatment
